Download Document 8369091

LUNGMARK Lung Cancer Biomarkers Overview -­‐ LUNGMARK: a blood test for lung cancer diagnosis We have discovered a group of 6 molecules, known as microRNA biomarkers, circula<ng in the bloodstream and associated with the presence of the deadliest form of lung cancer (adenocarcinoma; the single biggest cancer killer in the world). These can be tested for using simple PCR methods. The Problem Possible Applica@ons Lung adenocarcinoma is the biggest cancer killer There is currently no blood test for lung cancer diagnosis or prognosis. LUNGMARK has poten<al to be this test. •  There is no blood test available for its diagnosis •  80% are diagnosis a late stage when the tumour has spread •  ~20% of people diagnosed survive 1 year •  There currently is NO means of early diagnosis CLOSEST “GOLD-­‐STANDARD”: CT SCAN [we are also at an advanced stage with our discovery phase of breast and prostate cancer blood tests]
OUR SOLUTION: SIMPLE BLOOD TEST
•  When already some evidence of lung cancer: gold standard for confirmatory diagnosis [damaging X-­‐rays so only performed when there is already evidence] Market •  CT scans are expensive (> 10 <mes cost of blood test) Diagnos<cs •  limited availability to equipment IP Status •  many pa<ents wait longer for the CT than they live beyond diagnosis with lung cancer. Na<onalised applica<on US 13/601,703 SOLUTION: Blood test (so rela<vely painless for pa<ents: need <tea-­‐spoon of blood) with poten<al for diagnosis and on-­‐going monitoring CURRENT SOLUTION: CT SCAN
Patent pending Opportunity Research collabora<on Technology and Patent Status Available to license
This panel of microRNAs in blood was discovered using advanced microarray approaches. We have simplified it to now being simple polymerase chain reac<ons requiring very small volumes of blood. US patent 13/601,703 is pending. Researcher(s) Dr. Lorraine O’Driscoll [email protected] WHEN LUNG CANCER IS
ALREADY PRESENT OR
EVIDENCE OF LIKELIHOOD
OF LUNG CANCER:
The opportunity LUNGMARK is available for licensing to a company who is keen to increase their exports with minimally-­‐invasive cancer biomarkers. Dr. Emily Vereker, Alterna<vely, if you would like to con<nue research in this area, there are various support mechanisms and grants suitable for furthering the development of LUNGMARK in collabora<on with Dr. O’Driscoll, Dr. Rani and Prof. O’Byrne (Consultant Oncologist/Lung Cancer Specialist) at Trinity College Dublin. +353 1 896 4152 Contact Case Manager, Life Sciences [email protected] Reference: LO02-­‐310-­‐01